BioAge Labs
AUDIT: BioAge Labs — Refinancing the Hayflick Limit: The BioAge Reckoning
An objective clinical audit of BioAge Labs and their primary asset BGE-102. Examining Phase 1 biomarker data, hsCRP reduction, and the mechanistic realities of targeting cellular senescence versus downstream inflammation.